Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan
  
Shanghai Henlius Biotech will mainly tweak the safety profile of its PD-L1-targeting ADC HLX43 in Phase II clincial trials. (Shutterstock)

More from Clinical Trials

More from ASCO